Atopy

Pimecrolimus, tacrolimus, and moderate-potency topical corticosteroids come out on top

Risk increased with severity of atopic dermatitis across both groups, cohort study shows

Constellation of comorbid allergic conditions common among children

Early skin treatment in infants reduced weight and height compared with conventional approach

Suggests OA is not just about wear and tear

Disease status, itch improved significantly within 1 to 2 weeks with roflumilast cream

Black and multiracial children had the greatest increases in eczema

Key clinical outcomes, inflammatory biomarkers significantly reduced with or without steroids

With favorable results from three trials, approval seems likely

Elevated TARC at 2 months more than quadrupled the likelihood of moderate-severe AD at 2 years

Efficacy, safety maintained for up to 2 years in separate studies of tralokinumab

Small advantages for abrocitinib, upadacitinib, but data still accumulating for all the players

Rapid responses in a majority of patients in small trial of eblasakimab

EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment